The resveratrol tetramer (-)-hopeaphenol inhibits type III secretion in the gram-negative pathogens Yersinia pseudotuberculosis and Pseudomonas aeruginosa

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Zetterström, Caroline E ^a   Hasselgren, Jenny ^b,d   Salin, Olli ^a   Davis, Rohan A ^c   Quinn, Ronald J ^c   Sundin, Charlotta ^a,b   Elofsson, Mikael ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b Creative Antibiotics Sweden AB   (Sweden)

^c GRIFFITH UNIVERSITY   (Australia)

^d UmanDiagnostics AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HOPEAPHENOL; PHENOL DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACILLUS SUBTILIS; BACTERIAL VIRULENCE; CHLAMYDIA TRACHOMATIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI K 12; GROWTH INHIBITION; HELA CELL; HOST PATHOGEN INTERACTION; KLEBSIELLA PNEUMONIAE; MICROCOCCUS LUTEUS; NONHUMAN; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; TYPE III SECRETION SYSTEM; WESTERN BLOTTING; YERSINIA PSEUDOTUBERCULOSIS;

BACTERIAL PROTEINS; BACTERIAL SECRETION SYSTEMS; BLOTTING, WESTERN; CHLAMYDIA TRACHOMATIS; HELA CELLS; HUMANS; PROTEIN TRANSPORT; PSEUDOMONAS AERUGINOSA; STILBENES; VIRULENCE; YERSINIA PSEUDOTUBERCULOSIS;

EID: 84891894494     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081969     Document Type: Article

References (69)

1. Clatworthy AE, Pierson E, Hung DT (2007) Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 3: 541-548. doi:10.1038/nchembio.2007.24. PubMed: 17710100.
2. Keyser P, Elofsson M, Rosell S, Wolf-Watz H (2008) Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against gram-negative bacteria. J Intern Med 264: 17-29. doi:10.1111/j.1365-2796.2008.01941.x. PubMed: 18393958.
3. Rasko DA, Sperandio V (2010) Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 9: 117-128. doi:10.1038/nrd3013. PubMed: 20081869.
4. Svensson A, Larsson A, Emtenäs H, Hedenström M, Fex T et al. (2001) Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. Chembiochem 2: 915-918. doi:10.1002/1439-7633(20011203)2:12. PubMed: 11948880.
5. Rasko DA, Moreira CG, Li DR, Reading NC, Ritchie JM et al. (2008) Targeting QseC signaling and virulence for antibiotic development. Science 321: 1078-1080. doi:10.1126/science.1160354. PubMed: 18719281.
6. Kauppi AM, Nordfelth R, Uvell H, Wolf-Watz H, Elofsson M (2003) Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem Biol 10: 241-249. doi:10.1016/S1074-5521(03)00046-2. PubMed: 12670538.
7. Hueck CJ (1998) Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol Mol Biol Rev 62: 379-433. PubMed: 9618447.
8. Cornelis GR (2002) The Yersinia Ysc-Yop "type III" weaponry. Nat Rev Mol Cell Biol 3: 742-752. doi:10.1038/nrm932. PubMed: 12360191.
9. Peters J, Wilson DP, Myers G, Timms P, Bavoil PM (2007) Type III secretion à la Chlamydia. Trends Microbiol 15: 241-251. doi:10.1016/j.tim.2007.04.005. PubMed: 17482820.
10. Gauthier A, Robertson ML, Lowden M, Ibarra JA, Puente JL et al. (2005) Transcriptional inhibitor of virulence factors in enteropathogenic Escherichia coli. Antimicrob Agents Ch 49: 4101-4109. doi:10.1128/AAC.49.10.4101-4109.2005. PubMed: 16189086.
11. Felise HB, Nguyen HV, Pfuetzner RA, Barry KC, Jackson SR et al. (2008) An inhibitor of gram-negative bacterial virulence protein secretion. Cell Host Microbe 4: 325-336. doi:10.1016/j.chom.2008.08.001. PubMed: 18854237.
12. Pan NJ, Brady MJ, Leong JM, Goguen JD (2009) Targeting type III secretion in Yersinia pestis. Antimicrob Agents Chemother 53: 385-392. doi:10.1128/AAC.00670-08. PubMed: 19015348.
13. Aiello D, Williams JD, Majgier-Baranowska H, Patel I, Peet NP et al. (2010) Discovery and characterization of inhibitors of Pseudomonas aeruginosa type III secretion. Antimicrob Agents Chemother 54: 1988-1999. doi:10.1128/AAC.01598-09. PubMed: 20176902.
14. Li Y, Peng Q, Selimi D, Wang Q, Charkowski AO et al. (2009) The plant phenolic compound p-coumaric acid represses gene expression in the Dickeya dadantii type III secretion system. Appl Environ Microbiol 75: 1223-1228. doi:10.1128/AEM.02015-08. PubMed: 19114532.
15. Yamazaki A, Li J, Zeng Q, Khokhani D, Hutchins WC et al. (2011) Derivatives of plant phenolic compound affect the type III secretion system of Pseudomonas aeruginosa via a GacS-GacA two-component signal transduction system. Antimicrob Agents Ch 56: 36-43.
16. Harmon DE, Davis AJ, Castillo C, Mecsas J (2010) Identification and characterization of small-molecule inhibitors of Yop translocation in Yersinia pseudotuberculosis. Antimicrob Agents Chemother 54: 3241-3254. doi:10.1128/AAC.00364-10. PubMed: 20498321.
17. Garrity-Ryan LK, Kim OK, Balada-Llasat JM, Bartlett VJ, Verma AK et al. (2010) Small molecule inhibitors of LcrF, a Yersinia pseudotuberculosis transcription factor, attenuate virulence and limit infection in a murine pneumonia model. Infect Immun 78: 4683-4690. doi:10.1128/IAI.01305-09. PubMed: 20823209.
18. Swietnicki W, Carmany D, Retford M, Guelta M, Dorsey R et al. (2011) Identification of small-molecule inhibitors of Yersinia pestis type III secretion system YscN ATPase. PLOS ONE 6: e19716. doi:10.1371/journal.pone. 0019716. PubMed: 21611119.
19. Larzábal M, Mercado EC, Vilte DA, Salazar-González H, Cataldi A et al. (2010) Designed coiled-coil peptides inhibit the type three secretion system of enteropathogenic Escherichia coli. PLOS ONE 5: e9046. doi:10.1371/journal.pone.0009046. PubMed: 20140230.
20. Arnoldo A, Curak J, Kittanakom S, Chevelev I, Lee VT et al. (2008) Identification of small molecule inhibitors of Pseudomonas aeruginosa exoenzyme S using a yeast phenotypic screen. PLoS Genet 4: e1000005. PubMed: 18454192.
21. Enquist P-A, Gylfe Å, Hägglund U, Lindström P, Norberg-Scherman H et al. (2012) Derivatives of 8-hydroxyquinoline-antibacterial agents that target intra- and extracellular gram-negative pathogens. Bioorg Med Chem Lett 22: 3550-3553. doi:10.1016/j.bmcl.2012.03.096. PubMed: 22525317.
22. Kline T, Felise HB, Sanowar S, Miller SI (2012) The type III secretion system as a source of novel antibacterial drug targets. Curr Drug Targets 13: 338-351. doi:10.2174/138945012799424642. PubMed: 22206256.
23. Duncan MC, Linington RG, Auerbuch V (2012) Chemical inhibitors of the type three secretion system: disarming bacterial pathogens. Antimicrob Agents Chemother 56: 5433-5441. doi:10.1128/AAC.00975-12. PubMed: 22850518.
24. Tsou LK, Dossa PD, Hang HC (2012) Small molecules aimed at type III secretion systems to inhibit bacterial virulence. Med. Chem Commun 4: 68.
25. Kauppi AM, Nordfelth R, Hägglund U, Wolf-Watz H, Elofsson M (2004) Salicylanilides are potent inhibitors of type III secretion in Yersinia. Boston: Adv Exp Med Biol 529: 97-100.
26. Nordfelth R, Kauppi AM, Norberg HA, Wolf-Watz H, Elofsson M (2005) Small-molecule inhibitors specifically targeting type III secretion. Infect Immun 73: 3104-3114. doi:10.1128/IAI.73.5.3104-3114.2005. PubMed: 15845518.
27. Kauppi AM, Andersson CD, Norberg HA, Sundin C, Linusson A et al. (2007) Inhibitors of type III secretion in Yersinia: design, synthesis and multivariate QSAR of 2-arylsulfonylamino-benzanilides. Bioorg Med Chem 15: 6994-7011. doi:10.1016/j.bmc.2007.07.047. PubMed: 17851084.
28. Dahlgren MK, Kauppi AM, Olsson I-M, Linusson A, Elofsson M (2007) Design, synthesis, and multivariate quantitative structure-activity relationship of salicylanilides - potent inhibitors of type III secretion in Yersinia. J Med Chem 50: 6177-6188. doi:10.1021/jm070741b. PubMed: 17975903.
29. Dahlgren MK, Zetterström CE, Gylfe S, Linusson A, Elofsson M (2010) Statistical molecular design of a focused salicylidene acylhydrazide library and multivariate QSAR of inhibition of type III secretion in the gram-negative bacterium Yersinia. Bioorg Med Chem 18: 2686-2703. doi:10.1016/j.bmc.2010.02. 022. PubMed: 20219378.
30. Wang D, Zetterström CE, Gabrielsen M, Beckham KSH, Tree JJ et al. (2011) Identification of bacterial target proteins for the salicylidene acylhydrazide class of virulence-blocking compounds. J Biol Chem 286: 29922-29931. doi:10.1074/jbc.M111.233858. PubMed: 21724850.
31. Chu H, Slepenkin A, Elofsson M, Keyser P, la Maza de LM et al. (2010) Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseria gonorrhoeae. Int J Antimicrob Ag 36: 145-150. doi:10.1016/j. ijantimicag.2010.03.018. Available online at: doi:10.1016/j.ijantimicag.2010.03. 018
32. Forthal DN, Phan TB, Slepenkin AV, Landucci G, Chu H et al. (2012) In vitro anti-HIV-1 activity of salicylidene acylhydrazide compounds. Int J Antimicrob Agents 40: 354-360. doi:10.1016/j.ijantimicag.2012.05.023. PubMed: 22819150.
33. Linington RG, Robertson M, Gauthier A, Finlay BB, van Soest R et al. (2002) Caminoside A, an antimicrobial glycolipid isolated from the marine sponge Caminus sphaeroconia. Org Lett 4: 4089-4092. doi:10.1021/ol0268337. PubMed: 12423093.
34. Linington RG, Robertson M, Gauthier A, Finlay BB, MacMillan JB et al. (2006) Caminosides B-D, antimicrobial glycolipids isolated from the marine sponge Caminus sphaeroconia. J Nat Prod 69: 173-177. doi:10.1021/np050192h. PubMed: 16499312.
35. Iwatsuki M, Uchida R, Yoshijima H, Ui H, Shiomi K et al. (2008) Guadinomines, type III secretion system inhibitors, produced by Streptomyces sp. K01-0509. I: taxonomy, fermentation, isolation and biological properties. J Antibiot (Tokyo) 61: 222-229. doi:10.1038/ja.2008.32. PubMed: 18503201.
36. Iwatsuki M, Uchida R, Yoshijima H, Ui H, Shiomi K et al. (2008) Guadinomines, type III secretion system inhibitors, produced by Streptomyces sp. K01-0509. II: physico-chemical properties and structure elucidation. J Antibiot (Tokyo) 61: 230-236. doi:10.1038/ja.2008.33. PubMed: 18503202.
37. Kimura K, Iwatsuki M, Nagai T, Matsumoto A, Takahashi Y et al. (2010) A small-molecule inhibitor of the bacterial type III secretion system protects against in vivo infection with Citrobacter rodentium. J Antibiot: 1-7.
38. Parmeggiani A, Swart GWM (1985) Mechanism of action of kirromycin-like antibiotics. Annu Rev Microbiol 39: 557-577. doi:10.1146/annurev.mi.39.100185. 003013. PubMed: 3904612.
39. Yin S, Davis RA, Shelper T, Sykes ML, Avery VM et al. (2011) Pseudoceramines A-D, new antibacterial bromotyrosine alkaloids from the marine sponge Pseudoceratina sp. Org Biomol Chem 9: 6755-6760. doi:10.1039/c1ob05581j. PubMed: 21850326.
40. Hillgren JM, Oberg CT, Elofsson M (2012) Syntheses of pseudoceramines A-D and a new synthesis of spermatinamine, bromotyrosine natural products from marine sponges. Org Biomol Chem 10: 1246-1254. doi:10.1039/c1ob06722b. PubMed: 22179542.
41. Camp D, Davis RA, Campitelli M, Ebdon J, Quinn RJ (2012) Drug-like properties: guiding principles for the design of natural product libraries. J Nat Prod 75: 72-81. doi:10.1021/np200687v. PubMed: 22204643.
42. Liu JY, Ye YH, Wang L, Shi DH, Tan RX (2005) New resveratrol oligomers from the stem bark of Hopea hainanensis. Helvetica Chimica Acta 88: 2910-2917. doi:10.1002/hlca.200590234.
43. Creasy LL, Siemann EH (1992) Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic 43: 49-52.
44. Kondratyuk TP, Pezzuto JM (2004) Natural product polyphenols of relevance to human health. Pharm Biol 42: 46-63. doi:10.3109/13880200490893519.
45. Quideau S, Deffieux D, Douat-Casassus C, Pouységu L (2011) Plant polyphenols: chemical properties, biological activities, and synthesis. Angew Chem Int Ed Engl 50: 586-621. doi:10.1002/anie.201000044. PubMed: 21226137.
46. Snyder SA, Zografos AL, Lin Y (2007) Total synthesis of resveratrol-based natural products: a chemoselective solution. Angew Chem Int Ed Engl 46: 8186-8191. doi:10.1002/anie.200703333. PubMed: 17890663.
47. Snyder SA, Breazzano SP, Ross AG, Lin Y, Zografos AL (2009) Total synthesis of diverse carbogenic complexity within the resveratrol class from a common building block. J Am Chem Soc 131: 1753-1765. doi:10.1021/ja806183r. PubMed: 19143488.
48. Nicolaou KC, Wu TR, Kang Q, Chen DYK (2009) Total synthesis of hopeahainol A and hopeanol. Angew Chem - Int Ed 48: 3440-3443. doi:10.1002/anie.200900438.
49. Tree JJ, Wang D, McInally C, Mahajan A, Layton A et al. (2009) Characterization of the effects of salicylidene acylhydrazide compounds on type III secretion in Escherichia coli O157:H7. Infect Immun 77: 4209-4220. doi:10.1128/IAI.00562-09. PubMed: 19635828.
50. Charpentier X, Oswald E (2004) Identification of the secretion and translocation domain of the enteropathogenic and enterohemorrhagic Escherichia coli effector Cif, using TEM-1 beta-lactamase as a new fluorescence-based reporter. J Bacteriol 186: 5486-5495. doi:10.1128/JB.186.16.5486-5495.2004. PubMed: 15292151.
51. Marketon MM, DePaolo RW, DeBord KL, Jabri B, Schneewind O (2005) Plague bacteria target immune cells during infection. Science 309: 1739-1741. doi:10.1126/science.1114580. PubMed: 16051750.
52. Akopyan K, Edgren T, Wang-Edgren H, Rosqvist R, Fahlgren A et al. (2011) Translocation of surface-localized effectors in type III secretion. Proc Natl Acad Sci U S A 108: 1639-1644. doi:10.1073/pnas.1013888108. PubMed: 21220342.
53. Bodey GP, Bolivar R, Fainstein V, Jadeja L (1983) Infections caused by Pseudomonas aeruginosa. Clinical Infectious Diseases 5: 279-313. doi:10.1093/clinids/5.2.279.
54. Kanj SS, Kanafani ZA (2011) Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum β-lactamase-producing enterobacteriaceae, carbapenem-resistant enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 86: 250-259. doi:10.4065/mcp.2010.0674. PubMed: 21364117.
55. Breidenstein EBM, la Fuente-Núñez de C, Hancock REW (2011) Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 19: 419-426. doi:10.1016/j.tim.2011.04.005. PubMed: 21664819.
56. Frank DW (1997) The exoenzyme S regulon of Pseudomonas aeruginosa - Frank - 2003 - Molecular Microbiology - Wiley Online Library. Mol Microbiol 26: 621-629. doi:10.1046/j.1365-2958.1997.6251991.x. PubMed: 9427393.
57. Wolf K, Betts HJ, Chellas-Géry B, Hower S, Linton CN et al. (2006) Treatment of Chlamydia trachomatis with a small molecule inhibitor of the Yersinia type III secretion system disrupts progression of the chlamydial developmental cycle. Mol Microbiol 61: 1543-1555. doi:10.1111/j.1365-2958.2006. 05347.x. PubMed: 16968227.
58. Muschiol S, Bailey L, Gylfe Å, Sundin C, Hultenby K et al. (2006) A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc Natl Acad Sci U S A 103: 14566-14571. doi:10.1073/pnas.0606412103. PubMed: 16973741.
59. Slepenkin A, Chu H, Elofsson M, Keyser P, Peterson EM (2011) Protection of mice from a Chlamydia trachomatis vaginal infection using a salicylidene acylhydrazide, a potential microbicide. J Infect Dis 204: 1313-1320. doi:10.1093/infdis/jir552. PubMed: 21933873.
60. Bailey L, Gylfe Å, Sundin C, Muschiol S, Elofsson M et al. (2007) Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle. FEBS Lett 581: 587-595. doi:10.1016/j.febslet.2007. 01.013. PubMed: 17257594.
61. Negrea A, Bjur E, Ygberg SE, Elofsson M, Wolf-Watz H et al. (2007) Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother 51: 2867-2876. doi:10.1128/AAC.00223-07. PubMed: 17548496.
62. Veenendaal AKJ, Sundin C, Blocker AJ (2009) Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton. J Bacteriol 191: 563-570. doi:10.1128/JB.01004-08. PubMed: 18996990.
63. Yang F, Korban SS, Pusey PL, Elofsson M, Sundin GW et al. (2013) Small-molecule inhibitors suppress the expression of both type III secretion and amylovoran biosynthesis genes in Erwinia amylovora. Mol Plant Pathol: ([MedlinePgn:]) doi:10.1111/mpp.12064. PubMed: 23915008.
64. Heinzen RA, Hackstadt T (1997) The Chlamydia trachomatis parasitophorous vacuolar membrane is not passively permeable to low-molecular-weight compounds. Infect Immun 65: 1088-1094. PubMed: 9038320.
65. Ur-Rehman T, Nordfelth R, Blomgren A, Zetterström CE, Elofsson M et al. (2012) Preliminary pharmacokinetics of the bacterial virulence inhibitor n′-(3,5-dibromo-2-hydroxy-benzylidenene)-nicotinic acid hydrazide. Adv Exp Med Biol 954: 349-356. doi:10.1007/978-1-4614-3561-7-42. PubMed: 22782781.
66. Bölin I, Wolf-Watz H (1984) Molecular cloning of the temperature-inducible outer membrane protein 1 of Yersinia pseudotuberculosis. Infect Immun 43: 72-78. PubMed: 6317574.
67. Forsberg A, Rosqvist R (1993) In vivo expression of virulence genes of Yersinia pseudotuberculosis. Infect Agents Dis 2: 275-278. PubMed: 8173809.
68. Håkansson S, Schesser K, Persson C, Galyov EE, Rosqvist R et al. (1996) The YopB protein of Yersinia pseudotuberculosis is essential for the translocation of Yop effector proteins across the target cell plasma membrane and displays a contact-dependent membrane disrupting activity. EMBO J 15: 5812-5823. PubMed: 8918459.
69. Frank DW, Nair G, Schweizer HP (1994) Construction and characterization of chromosomal insertional mutations of the Pseudomonas aeruginosa exoenzyme S trans-regulatory locus. Infect Immun 62: 554-563. PubMed: 8300213.